At the molecular level, gliosarcomas including those in the pediatric age group demonstrate Phosphatase and Tensin homolog (PTEN) and TP53 mutations and Cyclin-dependent kinase inhibitor 2A (CDKN2A) deletions. The gene discussed is CDKN2A; the disease is gliosarcoma.